Key Takeaway: The article discusses a transcriptomic analysis of sigma-2 receptor modulators CT1812 and CT2168 in a mouse model of Alzheimer's disease. The findings were presented at the Society for Neuroscience annual meeting in November 2023. This research aims to enhance understanding of the role these modulators may play in treating Alzheimer's.
Price reaction · baseline $1 (2023-11-09 close) · hit pre-market · clean, no other CGTX news in the window
day 0 close · peak
+6.5%
day 1
+3%
day 3
+5%
Market Sentiment Analysis
POSITIVE FACTORS
The study presents new insights into Alzheimer's disease treatment.
CT1812 and CT2168 show potential as sigma-2 receptor modulators.
Research contributes to understanding neurodegenerative diseases.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
8.3%
average across 6 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Oxytocin
Phase 2 · Oxidative Stress
Full Press Release Details
Caldwell J, Cho E, Knezovich N, et al. A transcriptomic analysis to investigate the role of sigma-2 receptor modulators CT1812 and CT2168 in a mouse model of Alzheimer’s disease . Poster presented Nov 2023 at: Society for Neuroscience (SfN) annual meeting ; Washington DC.
Frequently Asked Questions
What are CT1812 and CT2168?
CT1812 and CT2168 are sigma-2 receptor modulators investigated for Alzheimer's treatment.
Where was the research presented?
The research was presented at the Society for Neuroscience annual meeting in Washington DC.
What is the focus of the study?
The study focuses on the role of sigma-2 receptor modulators in a mouse model of Alzheimer's disease.